Marc Hild
Marc Hild has a total of 133 co-authors. Here are the top co-authors by number of shared publications:
- Jeremy L. Jenkins
Novartis Biomedical Research, Cambridge, MA, USA
6 shared publications - Bosco Leung
Cell Biology Program, The Hospital for Sick Children, Toronto, Canada
2 shared publications - Caroline Gubser Keller
Discovery Sciences, Novartis Biomedical Research, Basel, Switzerland
2 shared publications Chian Yang
Novartis Institutes for Biomedical Research, Cambridge, MA, USA
2 shared publications- Frederic Sigoillot
Novartis Biomedical Research, Cambridge, MA, USA
2 shared publications - Hyelim Cho
Novartis Institutes for Biomedical Research, 181 Massachusetts Avenue, Cambridge, MA 02139, USA
2 shared publications
Latest Publications
- 11 November 2026
- Published by Springer Nature in Nature Chemical Biology
A conformation-sensitive product inhibitor of HDAC1/2 potentiates WNT signaling
Pharmacological enhancement of WNT/β-catenin signaling holds promises for tissue repair and regeneration. Here, we identify WNA1, an isoxazole-based small molecule, as a potent activator of WNT/β-catenin signaling. WNA1 stimulates β-catenin signaling in WNT-dependent manner and promotes skin hair growth in vivo. Intriguingly, WNA1 increases histone acetylation with minimal activity on uncomplexed recombinant histone deacetylases (HDACs), while conventional HDAC inhibitors exhibit minimal β-catenin-stabilizing activity. We demonstrate that β-catenin signaling is repressed by the HDAC1/2-containing NuRD complex and WNA1 enhances β-catenin signaling by selectively inhibiting HDAC1/2. Structural and biochemical analyses reveal that WNA1 is hydrolyzed by the HDAC1-MTA1 complex and its product is trapped in the foot pocket of HDAC1 in an inositol-hexaphosphate-dependent manner. HDAC1 mutants with reduced foot pocket abrogate WNA1-induced histone acetylation and β-catenin accumulation. These findings establish WNA1 as a conformation-sensitive, foot-pocket-anchored product inhibitor selectively targeting complex-bound HDAC1/2 and reveal a unique mechanism for HDAC1/2 inhibition and WNT potentiation.
- 11 November 2026
- Published by Springer Nature in Nature Chemical Biology
A conformation-sensitive product inhibitor of HDAC1/2 potentiates WNT signaling
Pharmacological enhancement of WNT/β-catenin signaling holds promises for tissue repair and regeneration. Here, we identify WNA1, an isoxazole-based small molecule, as a potent activator of WNT/β-catenin signaling. WNA1 stimulates β-catenin signaling in WNT-dependent manner and promotes skin hair growth in vivo. Intriguingly, WNA1 increases histone acetylation with minimal activity on uncomplexed recombinant histone deacetylases (HDACs), while conventional HDAC inhibitors exhibit minimal β-catenin-stabilizing activity. We demonstrate that β-catenin signaling is repressed by the HDAC1/2-containing NuRD complex and WNA1 enhances β-catenin signaling by selectively inhibiting HDAC1/2. Structural and biochemical analyses reveal that WNA1 is hydrolyzed by the HDAC1-MTA1 complex and its product is trapped in the foot pocket of HDAC1 in an inositol-hexaphosphate-dependent manner. HDAC1 mutants with reduced foot pocket abrogate WNA1-induced histone acetylation and β-catenin accumulation. These findings establish WNA1 as a conformation-sensitive, foot-pocket-anchored product inhibitor selectively targeting complex-bound HDAC1/2 and reveal a unique mechanism for HDAC1/2 inhibition and WNT potentiation.
- Open Access
- 3 March 2022
- Published by Springer Nature in Nature Communications
- Vol. 13 (1) , 1-11
An orally available, brain penetrant, small molecule lowers huntingtin levels by enhancing pseudoexon inclusion
Huntington’s Disease (HD) is a progressive neurodegenerative disorder caused by CAG trinucleotide repeat expansions in exon 1 of the huntingtin (HTT) gene. The mutant HTT (mHTT) protein causes neuronal dysfunction, causing progressive motor, cognitive and behavioral abnormalities. Current treatments for HD only alleviate symptoms, but cerebral spinal fluid (CSF) or central nervous system (CNS) delivery of antisense oligonucleotides (ASOs) or virus vectors expressing RNA-induced silencing (RNAi) moieties designed to induce mHTT mRNA lowering have progressed to clinical trials. Here, we present an alternative disease modifying therapy the orally available, brain penetrant small molecule branaplam. By promoting inclusion of a pseudoexon in the primary transcript, branaplam lowers mHTT protein levels in HD patient cells, in an HD mouse model and in blood samples from Spinal Muscular Atrophy (SMA) Type I patients dosed orally for SMA (NCT02268552). Our work paves the way for evaluating branaplam’s utility as an HD therapy, leveraging small molecule splicing modulators to reduce expression of dominant disease genes by driving pseudoexon inclusion.
- 3 March 2022
- Published by Springer Nature in Nature Communications
- Vol. 13 (1) , 1-11
Open AccessAn orally available, brain penetrant, small molecule lowers huntingtin levels by enhancing pseudoexon inclusion
Huntington’s Disease (HD) is a progressive neurodegenerative disorder caused by CAG trinucleotide repeat expansions in exon 1 of the huntingtin (HTT) gene. The mutant HTT (mHTT) protein causes neuronal dysfunction, causing progressive motor, cognitive and behavioral abnormalities. Current treatments for HD only alleviate symptoms, but cerebral spinal fluid (CSF) or central nervous system (CNS) delivery of antisense oligonucleotides (ASOs) or virus vectors expressing RNA-induced silencing (RNAi) moieties designed to induce mHTT mRNA lowering have progressed to clinical trials. Here, we present an alternative disease modifying therapy the orally available, brain penetrant small molecule branaplam. By promoting inclusion of a pseudoexon in the primary transcript, branaplam lowers mHTT protein levels in HD patient cells, in an HD mouse model and in blood samples from Spinal Muscular Atrophy (SMA) Type I patients dosed orally for SMA (NCT02268552). Our work paves the way for evaluating branaplam’s utility as an HD therapy, leveraging small molecule splicing modulators to reduce expression of dominant disease genes by driving pseudoexon inclusion.
- Open Access
- 22 October 2021
- Published by Springer Nature in Nature Communications
- Vol. 12 (1) , 1-12
Engineering digitizer circuits for chemical and genetic screens in human cells
Cell-based transcriptional reporters are invaluable in high-throughput compound and CRISPR screens for identifying compounds or genes that can impact a pathway of interest. However, many transcriptional reporters have weak activities and transient responses. This can result in overlooking therapeutic targets and compounds that are difficult to detect, necessitating the resource-consuming process of running multiple screens at various timepoints. Here, we present RADAR, a digitizer circuit for amplifying reporter activity and retaining memory of pathway activation. Reporting on the AP-1 pathway, our circuit identifies compounds with known activity against PKC-related pathways and shows an enhanced dynamic range with improved sensitivity compared to a classical reporter in compound screens. In the first genome-wide pooled CRISPR screen for the AP-1 pathway, RADAR identifies canonical genes from the MAPK and PKC pathways, as well as non-canonical regulators. Thus, our scalable system highlights the benefit and versatility of using genetic circuits in large-scale cell-based screening.
- 22 October 2021
- Published by Springer Nature in Nature Communications
- Vol. 12 (1) , 1-12
Open AccessEngineering digitizer circuits for chemical and genetic screens in human cells
Cell-based transcriptional reporters are invaluable in high-throughput compound and CRISPR screens for identifying compounds or genes that can impact a pathway of interest. However, many transcriptional reporters have weak activities and transient responses. This can result in overlooking therapeutic targets and compounds that are difficult to detect, necessitating the resource-consuming process of running multiple screens at various timepoints. Here, we present RADAR, a digitizer circuit for amplifying reporter activity and retaining memory of pathway activation. Reporting on the AP-1 pathway, our circuit identifies compounds with known activity against PKC-related pathways and shows an enhanced dynamic range with improved sensitivity compared to a classical reporter in compound screens. In the first genome-wide pooled CRISPR screen for the AP-1 pathway, RADAR identifies canonical genes from the MAPK and PKC pathways, as well as non-canonical regulators. Thus, our scalable system highlights the benefit and versatility of using genetic circuits in large-scale cell-based screening.
- 1 June 2021
- Published by Elsevier in Cell Chemical Biology
- Vol. 28 (6) , 802-812.e6
An IMiD-inducible degron provides reversible regulation for chimeric antigen receptor expression and activity
- 1 June 2021
- Published by Elsevier in Cell Chemical Biology
- Vol. 28 (6) , 802-812.e6
An IMiD-inducible degron provides reversible regulation for chimeric antigen receptor expression and activity
- 31 March 2021
- Published by Elsevier in Cell Chemical Biology
- Vol. 28 (10) , 1407-1419.e6
CYP27A1-dependent anti-melanoma activity of limonoid natural products targets mitochondrial metabolism
- 31 March 2021
- Published by Elsevier in Cell Chemical Biology
- Vol. 28 (10) , 1407-1419.e6
CYP27A1-dependent anti-melanoma activity of limonoid natural products targets mitochondrial metabolism
- Open Access
- 17 October 2018
- Published by Springer Nature in Nature Communications
- Vol. 9 (1) , 1-9
DRUG-seq for miniaturized high-throughput transcriptome profiling in drug discovery
Here we report Digital RNA with pertUrbation of Genes (DRUG-seq), a high-throughput platform for drug discovery. Pharmaceutical discovery relies on high-throughput screening, yet current platforms have limited readouts. RNA-seq is a powerful tool to investigate drug effects using transcriptome changes as a proxy, yet standard library construction is costly. DRUG-seq captures transcriptional changes detected in standard RNA-seq at 1/100th the cost. In proof-of-concept experiments profiling 433 compounds across 8 doses, transcription profiles generated from DRUG-seq successfully grouped compounds into functional clusters by mechanism of actions (MoAs) based on their intended targets. Perturbation differences reflected in transcriptome changes were detected for compounds engaging the same target, demonstrating the value of using DRUG-seq for understanding on and off-target activities. We demonstrate DRUG-seq captures common mechanisms, as well as differences between compound treatment and CRISPR on the same target. DRUG-seq provides a powerful tool for comprehensive transcriptome readout in a high-throughput screening environment.
- 17 October 2018
- Published by Springer Nature in Nature Communications
- Vol. 9 (1) , 1-9
Open AccessDRUG-seq for miniaturized high-throughput transcriptome profiling in drug discovery
Here we report Digital RNA with pertUrbation of Genes (DRUG-seq), a high-throughput platform for drug discovery. Pharmaceutical discovery relies on high-throughput screening, yet current platforms have limited readouts. RNA-seq is a powerful tool to investigate drug effects using transcriptome changes as a proxy, yet standard library construction is costly. DRUG-seq captures transcriptional changes detected in standard RNA-seq at 1/100th the cost. In proof-of-concept experiments profiling 433 compounds across 8 doses, transcription profiles generated from DRUG-seq successfully grouped compounds into functional clusters by mechanism of actions (MoAs) based on their intended targets. Perturbation differences reflected in transcriptome changes were detected for compounds engaging the same target, demonstrating the value of using DRUG-seq for understanding on and off-target activities. We demonstrate DRUG-seq captures common mechanisms, as well as differences between compound treatment and CRISPR on the same target. DRUG-seq provides a powerful tool for comprehensive transcriptome readout in a high-throughput screening environment.
- Open Access
- 5 June 2018
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 3 (6) , 6097-6103
Indolyl-Pyridinyl-Propenone-Induced Methuosis through the Inhibition of PIKFYVE
Methuosis is a form of nonapoptotic cell death characterized by the accumulation of macropinosome-derived vacuoles. Herein, we identify PIKFYVE, a class III phosphoinositide (PI) kinase, as the protein target responsible for the methuosis-inducing activity of indolyl-pyridinyl-propenones (3-(5-methoxy-2-methyl-1H-indol-3-yl)-1-(4-pyridinyl)-2-propen-1-one). We further characterize the effects of chemical substitutions at the 2- and 5-indolyl positions on cytoplasmic vacuolization and PIKFYVE binding and inhibitory activity. Our study provides a better understanding of the mechanism of methuosis-inducing indolyl-pyridinyl-propenones.
- 5 June 2018
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 3 (6) , 6097-6103
Open AccessIndolyl-Pyridinyl-Propenone-Induced Methuosis through the Inhibition of PIKFYVE
Methuosis is a form of nonapoptotic cell death characterized by the accumulation of macropinosome-derived vacuoles. Herein, we identify PIKFYVE, a class III phosphoinositide (PI) kinase, as the protein target responsible for the methuosis-inducing activity of indolyl-pyridinyl-propenones (3-(5-methoxy-2-methyl-1H-indol-3-yl)-1-(4-pyridinyl)-2-propen-1-one). We further characterize the effects of chemical substitutions at the 2- and 5-indolyl positions on cytoplasmic vacuolization and PIKFYVE binding and inhibitory activity. Our study provides a better understanding of the mechanism of methuosis-inducing indolyl-pyridinyl-propenones.
- Open Access
- 29 March 2018
- Published by eLife Sciences Publications, Ltd in eLife
- Vol. 7
Size uniformity of animal cells is actively maintained by a p38 MAPK-dependent regulation of G1-length
Animal cells within a tissue typically display a striking regularity in their size. To date, the molecular mechanisms that control this uniformity are still unknown. We have previously shown that size uniformity in animal cells is promoted, in part, by size-dependent regulation of G1 length. To identify the molecular mechanisms underlying this process, we performed a large-scale small molecule screen and found that the p38 MAPK pathway is involved in coordinating cell size and cell cycle progression. Small cells display higher p38 activity and spend more time in G1 than larger cells. Inhibition of p38 MAPK leads to loss of the compensatory G1 length extension in small cells, resulting in faster proliferation, smaller cell size and increased size heterogeneity. We propose a model wherein the p38 pathway responds to changes in cell size and regulates G1 exit accordingly, to increase cell size uniformity.
- 29 March 2018
- Published by eLife Sciences Publications, Ltd in eLife
- Vol. 7
Open AccessSize uniformity of animal cells is actively maintained by a p38 MAPK-dependent regulation of G1-length
Animal cells within a tissue typically display a striking regularity in their size. To date, the molecular mechanisms that control this uniformity are still unknown. We have previously shown that size uniformity in animal cells is promoted, in part, by size-dependent regulation of G1 length. To identify the molecular mechanisms underlying this process, we performed a large-scale small molecule screen and found that the p38 MAPK pathway is involved in coordinating cell size and cell cycle progression. Small cells display higher p38 activity and spend more time in G1 than larger cells. Inhibition of p38 MAPK leads to loss of the compensatory G1 length extension in small cells, resulting in faster proliferation, smaller cell size and increased size heterogeneity. We propose a model wherein the p38 pathway responds to changes in cell size and regulates G1 exit accordingly, to increase cell size uniformity.
- Open Access
Size uniformity of animal cells is actively maintained by a p38 MAPK-dependent regulation of G1-length
Animal cells within a tissue typically display a striking regularity in their size. To date, the molecular mechanisms that control this uniformity are still unknown. We have previously shown that size uniformity in animal cells is promoted, in part, by size-dependent regulation of G1 length. To identify the molecular mechanisms underlying this process, we performed a large-scale small molecule screen and found that the p38 MAPK pathway is involved in coordinating cell size and cell cycle progression. Small cells display higher p38 activity and spend more time in G1 than larger cells. Inhibition of p38 MAPK leads to loss of the compensatory G1 length extension in small cells, resulting in faster proliferation, smaller cell size and increased size heterogeneity. We propose a model wherein the p38 pathway responds to changes in cell size and regulates G1 exit accordingly, to increase cell size uniformity. One-sentence summary: The p38 MAP kinase pathway coordinates cell growth and cell cycle progression by lengthening G1 in small cells, allowing them more time to grow before their next division.
Open AccessSize uniformity of animal cells is actively maintained by a p38 MAPK-dependent regulation of G1-length
Animal cells within a tissue typically display a striking regularity in their size. To date, the molecular mechanisms that control this uniformity are still unknown. We have previously shown that size uniformity in animal cells is promoted, in part, by size-dependent regulation of G1 length. To identify the molecular mechanisms underlying this process, we performed a large-scale small molecule screen and found that the p38 MAPK pathway is involved in coordinating cell size and cell cycle progression. Small cells display higher p38 activity and spend more time in G1 than larger cells. Inhibition of p38 MAPK leads to loss of the compensatory G1 length extension in small cells, resulting in faster proliferation, smaller cell size and increased size heterogeneity. We propose a model wherein the p38 pathway responds to changes in cell size and regulates G1 exit accordingly, to increase cell size uniformity. One-sentence summary: The p38 MAP kinase pathway coordinates cell growth and cell cycle progression by lengthening G1 in small cells, allowing them more time to grow before their next division.
- 1 January 2000
- Published by Springer Nature
- No. 29,p. 81-106
The Roles of BMPs, BMP Antagonists, and the BMP Signaling Transducers Smad1 and Smad5 During Dorsoventral Patterning of the Zebrafish Embryo
- 1 January 2000
- Published by Springer Nature
- No. 29,p. 81-106
The Roles of BMPs, BMP Antagonists, and the BMP Signaling Transducers Smad1 and Smad5 During Dorsoventral Patterning of the Zebrafish Embryo